Objective There are no consistent data on the prevalence and bone status of normocalcaemic hypoparathyroidism (NHYPO) as defined by normal adjusted calcium and low PTH level. Our aim was to determine the prevalence and the metabolic bone profile of NHYPO in older women, assessing its evolution over time. The second objective was to evaluate the prevalence of other calcium metabolic disorders.
Background
Parathyroid hormone (PTH) is the major hormonal mediator of extracellular calcium homeostasis and regulates osteoclastic bone resorption, the renal excretion of calcium and synthesis of 1,25-dihydroxyvitamin D. Circulating PTH concentrations display a large interindividual variability which has a strong heritable component. [1] However, the genetic factors governing serum PTH concentrations remain to be elucidated. PTH is an 84 amino acid peptide, whose secretion by the parathyroid chief cells is regulated by the calcium-sensing receptor (CaSR), which is expressed at the parathyroid cell surface. Mutations of the CaSR gene lead to inherited forms of hypercalcaemia and hypocalcaemia, [2] and common coding region CaSR single nucleotide polymorphisms (SNPs) have been revealed as determinants of serum calcium concentrations. [3] Cusano et al. [4] recently reported the prevalence of normocalcaemic hyper-(NPHPT) and hypoparathyroidism (NHYPO) in two unselected, nonreferral community-dwelling populations, identifying a prevalence of 0·4-3·1% and 1·1-1·9%, respectively.
NPHPT is characterized by normal calcium levels with high PTH in the absence of secondary causes of hyperparathyroidism [5] and was officially recognized by the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. [6] These patients may develop a similar rate of low bone mineral density compared to subjects with primary hyperparathyroidism (PHPT) [7] and have a trend towards a higher recurrence of NPHPT after parathyroidectomy. [8] While NPHPT is a well-documented diagnostic category, no consistent data are available for NHYPO. The diagnosis of NHYPO has been used for patients who develop hypocalcaemia in response to bisphosphonate therapy having had normal calcium values and low PTH levels prior to starting therapy; such patients were considered to have inadequate parathyroid gland reserve. [9] We cannot yet be certain whether NHYPO is a real diagnostic category. Indeed, Cusano et al. [4] identified 68 subjects with NHYPO, none of whom developed overt hypoparathyroidism on follow-up; persistent disease was noted in only 2 of 26 subjects that concluded the follow-up period.
It is possible that the prevalence of NHYPO by Cusano et al. [4] may have underestimated the true prevalence in the general population because they only studied men and young women. It is important to study older women as many parathyroid diseases such as PHPT have their peak incidence in the first decade after the menopause. [10] [11] [12] The primary end-point of this study was to determine the prevalence and the metabolic bone profile of NHYPO in our population, assessing its evolution over the time. The secondary end-point was to evaluate the prevalence of other calcium metabolic disorders.
Materials and Methods

Study Design and Population
We recruited 2419 older women (age 55-79 years) and 258 younger women (age 30-40 years) from 5 European cities (the OPUS study). [13] The OPUS study is a large population-based cohort study designed to compare quantitative ultrasound (QUS) performance with central DXA. The study design has previously been reported. [13] Of note, exclusion criteria were limited to disorders that precluded valid QUS measurements (i.e. bilateral fractures of the calcaneus, bilateral hip prostheses, disorders of the hand), general inability to undergo the specified examinations, and cognitive limitations that precluded completion of self-administered questionnaires. Pregnant women were excluded because of potential risks associated with X-ray exposure. All investigations were conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the local ethics committees, and written informed consent was obtained from each subject.
The OPUS study became a longitudinal study when laboratory and other data were collected approximately 6 years later. Complete follow-up data are available in 1416 subjects. Each subject had a first visit (between 1999 and 2001) and then 6 years later was invited to attend for a second visit (between 2005 and 2007) . At the time of each study visit, a modified version of the European Vertebral Osteoporosis Study (EVOS) risk factor questionnaire [14] was administered to each subject. From this, we were able to collect medical and lifestyle information. Medical history of diseases and treatments was recorded. Nonfasting venous blood samples were collected from each subject between 12:00 and 15:00 into serum separating tubes. The blood was left to clot for 30 min at room temperature and centrifuged at 2500 g for 10 min. The serum was then collected and stored at −80 °C until analysis. Second morning void urine samples were collected and stored at −20 °C until analysis.
To estimate reference intervals for adjusted calcium and PTH, 107 young women were eligible after excluding those with low 25-hydroxyvitamin D (25OHD) (<50 nmol/l), eGFR < 60 ml/min per 1·73 m 2 , T-score at the lumbar spine or total hip equal to or less than −2·5 and those taking drugs or suffering from diseases known to affect bone (). Both adjusted serum calcium and PTH were log10-transformed prior to analysis. 
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Biochemical Measurements
Blood samples were drawn to measure serum:
1. Calcium and albumin measured using a Cobas c701 (Roche Diagnostics, Penzberg, Germany) autoanalyser in the Chemical Pathology laboratory, Sheffield Teaching Hospitals, UK. The manufacturer's reported interassay precision was <2·0% for each test. We calculated adjusted calcium in all subjects (pre-and postmenopausal women were included in the analysis) based on the total calcium and albumin measurements according to James' formula. [15] As recommended in that report, we excluded subjects with creatinine >200 μmol/and/or albumin <20 or >50 g/l and/or total calcium >3 mmol/l. In particular, at baseline, 2638 women were included in the analysis, and the local adjustment equation was expressed by the following relationship: adjusted Calcium = Total Calcium − (0·015 × albumin) + 0·699. After six-year follow-up (1652 women were included in the analysis), the local adjustment equation was expressed by the following relationship: adjusted Calcium = Total Calcium − (0·018 × albumin) + 1·581
2. Collagen type 1 cross-linked C-telopeptide (CTX), intact procollagen type 1 N propeptide (PINP), bone alkaline phosphatase (bone ALP), 25OHD and PTHi. They were measured in serum using the IDS-iSYS automated immunoassays (Immunodiagnostic Systems, Boldon, UK). The interassay coefficients of variation (CV) were 6·5%, 7·2%, 3·5%, 6·7% and 6·5%, respectively.
3. Creatinine, measured using the Cobas c 311 automated analyser (Roche Diagnostics). This was used to calculate the estimated glomerular filtration rate (eGFR) using the formula based on the modification of diet and renal disease (MDRD). [16] We measured the baseline and 6-year samples at the same time.
Bone Densitometry
At both visits, bone mineral density (BMD) was performed using dual-energy X-ray absorptiometry (DXA) of the lumbar spine and the proximal femur in posteroanterior projection (Hologic QDR-4500; Hologic, Bedford, MA, USA in the Kiel, Paris and Sheffield centres) or in anterior-posterior projection (Lunar Expert devices; GE Lunar, Madison, WI, USA in the Aberdeen and Berlin centres). Measurements were standardized and crosscalibrated across centres.
Statistical Analysis
To classify the abnormalities of calcium homeostasis, we used the following approach:
We calculated adjusted calcium in all subjects based on the total calcium and albumin measurements (as above). Reference intervals were calculated for adjusted serum calcium and PTH using data from the healthy premenopausal women. Both adjusted serum calcium and PTH were log10-transformed prior to analysis and the mean ± 1·96SD calculated (). We allocated older women (baseline) into one of eight categories using the ellipse defined by the Mahalanobis distance analysis ( Fig. 1 ) which measures how far each observation is from the centre of a data cluster, taking into account the shape of the cluster. Observations are considered outliers if
. We referred to 'high or low' if they were outside the ellipse and had values above or below those found in the young women. We referred to 'high or low normal' if they were outside the ellipse and had values above or below the mean found in the young women but within the reference interval. Normal was defined as anyone inside the ellipse at baseline. Hyperparathyroid hypercalcaemia (HH) that included both PHPT and familial hypocalciuric hypercalcaemia (FHH) was defined as anyone outside the ellipse with high adjusted calcium and high or high-normal PTH. NPHPT was defined as anyone outside the ellipse with normal adjusted calcium, high PTH, 25OHD > 50 nmol/l and eGFR > 60 ml/min. Secondary hyperparathyroidism was defined as anyone outside the ellipse with low adjusted calcium and high-normal PTH, low adjusted calcium and high PTH, low normal adjusted calcium and high PTH, high-normal adjusted calcium and high PTH with 25OHD < 50 nmol/l and/or eGFR < 60 ml/min. Hypoparathyroidism was defined as anyone outside the ellipse with low adjusted calcium and low or low-normal PTH. NHYPO was defined as anyone outside the ellipse with normal adjusted calcium and low PTH. Non-PTH hypercalcaemia was defined as anyone outside the ellipse with high adjusted calcium and low or low-normal PTH. Missing data patients were defined as anyone with missing calcium, PTH or albumin measurements. 
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Baseline data results for adjusted calcium and PTH. The ellipse was derived using Mahalanobis distances method to define normal (black) and abnormal (red) values. The horizontal and vertical lines indicate the geometric mean, and reference intervals described in Table 1 . The pink rectangle identifies subjects with normocalcaemic hypoparathyroidism.
We applied the same Mahalanobis distance analysis for the older women at follow-up (Fig. 2) . In this analysis, subjects were included if they had measurements for PTH, calcium and albumin at baseline and follow-up (N = 1416).
Figure 2.
Follow-up results for adjusted calcium and PTH. The ellipse was derived using Mahalanobis distances method to define normal (black) and abnormal (red) values. The horizontal and vertical lines indicate the geometric mean, and reference intervals obtained from the healthy young women. The pink rectangle identifies subjects with normocalcaemic hypoparathyroidism.
Descriptive Statistics
The subject characteristics were summarized using frequencies and percentages for categorical variables. For continuous variables, mean and standard deviation were calculated. Characteristics were compared between groups using anova. Post hoc tests compared all groups to the normal group using the Dunnett method. All measurements with a skewed distribution were log10-transformed prior to analysis, and differences between groups were back-transformed and expressed as a percentage difference. We performed multiple regression analyses examining the relationship between measurements at baseline and BMD T-score at baseline; and measurements at baseline and change in BMD from baseline to year 6. We examined the change in PTH measurement from baseline to 6 years in the overall population using a paired t-test. The α-level was set at 0·05.
Results
Subject Characteristics
The subject characteristics at baseline are shown in and . 
P-value* ns ns ns ns *P-value from anova testing for an overall difference in means.
Diagnostic Categories According to Calcium Metabolism Disorders at Baseline
We identified ( and ) 2063 subjects (85·3%) with no calcium abnormalities [normal adjusted calcium levels (2·4 mmol/l, 95% CI 2·39-2·41) and normal PTH (39 ng/l, 95% CI 38·4-39·7)]. 86 subjects (3·6%) were affected by HH [high calcium levels (2·79 mmol/l, 95% CI 2·78-2·80) and elevated PTH (58·8 ng/l, 95% CI 52·6-65·8)]. At the second visit (after 6 years), of the 56 PHPT subjects with follow-up data, 47 (2%) had persistent evidence of PHPT. One subject (0·1%) was affected by NPHPT, but none met the diagnostic criteria for NPHPT at the second visit. Sixty-nine subjects (2·8%) were affected by secondary hyperparathyroidism [low calcium (2·16 mmol/l, 95% CI 2·09-2·23)] with high or high-normal PTH (88·9 ng/l, 95% CI 75·8-104·3). Three subjects (0·1%) were affected by hypoparathyroidism. Fifty-seven subjects (2·4%) were affected by NHYPO [normal calcium (2·39 mmol/l, 95% CI 2·36-2·42) with low PTH (10·1 ng/l, 95% CI 9·2-11·1)]. Twelve subjects (0·5%) were affected by non-PTH hypercalcaemia [high calcium (2·82 mmol/l, 95% CI 2·75-2·89) with low or lownormal PTH (18·5 ng/l, 95% CI 16·2-21·3)]. 
Post-hoc testing for a difference in mean from the Normal group: *P-value < 0·050, **P-value < 0·001. †P-value from anova testing for an overall difference in means. P-value † 0·048 <0·001 <0·001 <0·001 †P-value from anova testing for an overall difference in means. Post hoc testing for a difference in mean from the normal group: *P-value <0·050, **P-value <0·010 and ***Pvalue <0·001.
Normocalcaemic Hypoparathyroidism
There were statistically significant differences when we compared the NHYPO group with the normal group in terms of BAP (difference = −15·4%, 95% CI: −26·2 to −3·0, P = 0·007), CTX (difference = −66·3%, 95% CI: −74·0 to −56·4, P < 0·001) and osteocalcin (difference = −36·8%, 95% CI: −45·6 to −26·6, P < 0·001). Baseline BMD parameters, and the lumbar spine and hip change over time were not significantly different compared to the normal group. At the second visit (after 6 years), of the 35 NHYPO subjects with follow-up data, none developed overt hypoparathyroidism and only 15 (0·6%) subjects had persistent evidence of NHYPO.
Comparisons Between the Different Categories and Normal Subjects
At baseline, no statistically significant differences were found between the different groups compared to normal subjects with regard to age, BMI and lumbar spine BMD ( and ). As expected from its definition, secondary hyperparathyroidism showed a statistically significant reduction in 25 (OH) vitamin D and eGFR compared to the normal group (respectively, difference = −15·9%, 95% CI: −27·2 to −2·8, P = 0·011; difference = −16·0%, 95% CI: −21·8 to −9·8, P < 0·001). Post-hoc testing for a difference in mean from the Normal group: *P-value < 0·050, **P-value < 0·001. †P-value from anova testing for an overall difference in means. P-value † 0·048 <0·001 <0·001 <0·001 †P-value from anova testing for an overall difference in means. Post hoc testing for a difference in mean from the normal group: *P-value <0·050, **P-value <0·010 and ***Pvalue <0·001.
In subjects with HH and non-PTH hypercalcaemia, there was a statistically significant reduction in eGFR compared to the normal group (respectively, difference = −11·7%, 95% CI: −17·4 to −5·7, P < 0·001; difference = −17·0%, 95% CI: −30·3 to −1·2, P = 0·024).
Metabolic Bone Parameters
BMD. At baseline, no significant differences were found between the different groups compared to normal subjects at the lumbar spine. Post hoc testing demonstrated a statistically significant difference in the mean hip T-score between the normal and secondary hyperparathyroidism group (difference = −0·47, 95% CI: −0·83 to −0·11, P = 0·004). The lumbar spine and hip BMD change over time (rate of bone loss per year from baseline) did not show any statistically significant differences between abnormal calcaemia categories compared to the normal group. Baseline total hip BMD was inversely related to serum PTH (R = −0·006, P < 0·001) and age (R = −0·058, P < 0·001), and positively associated with BMI (R = 0·105, P < 0·001). The change in total hip BMD was inversely related to serum calcium (R = −27·567, P < 0·001) and age (R = −0·425, P = 0·029) ( ). Bone Turnover Markers. CTX. We found a statistically significant difference between the normal group and the PHPT (difference = 24·0%, 95% CI: 1·5 to 51·3, P = 0·025), secondary hyperparathyroidism (difference = 28·1%, 95% CI: 2·8 to 59·5, P = 0·02) and non-PTH hypercalcaemia (difference = −54·6%, 95% CI: −73·2 to −23·3, P = 0·001) groups ( ). P-value † 0·048 <0·001 <0·001 <0·001 †P-value from anova testing for an overall difference in means. Post hoc testing for a difference in mean from the normal group: *P-value <0·050, **P-value <0·010 and ***Pvalue <0·001.
Osteocalcin. We found a statistically significant difference between the normal and secondary hyperparathyroidism groups (difference = 35·6%, 95% CI: 18·0 to 55·9, P < 0·001).
Bone ALP. We found a statistically significant difference between the normal and non-PTH hypercalcaemia groups (difference = −27·2%, 95% CI: −45·80 to −2·3, P = 0·023).
PINP. There were no statistically significant differences when we compared the normal group to other categories.
Stability of PTH Over Time.
In the overall population, there was a statistically significant change in PTH measurement from baseline. Mean PTH measurement increased from 41·6 ng/l (SD = 21·1) at baseline to 45·5 ng/l (SD = 26·1) at six years (mean change = 3·9 ng/l, 95% CI: 2·79 to 4·98, P < 0·001).
Discussion
This is the first study to investigate the prevalence of NHYPO in a large cohort of postmenopausal women. Cusano et al. [4] previously conducted a large trial to evaluate the epidemiology of these subclinical conditions in an unselected community-based sample of old men (The Osteoporotic Fractures in Men study, MrOS study), and in young men and premenopausal women (Dallas Heart Study, DHS), revealing a prevalence, respectively, of 0·4% and 3·1% for NPHPT and of 1·1% and 1·9%, respectively, for NHYPO. At baseline, we identified 57 subjects (2·4%) affected by NHYPO and just 1 subject (0·1%) affected by NPHPT after ruling out the main causes of secondary hyperparathyroidism (vitamin D deficiency, eGFR < 60 ml/min; only 6 NHYPO subjects were taking proton pump inhibitors). In our cohort, the prevalence of NHYPO is higher in comparison with the previous studies; this is probably due to differences in gender and age between the three populations.
Even if the baseline cross-sectional data indicated the existence of NHYPO as a new subclinical pathological category, the longitudinal data gave rise to many doubts. Indeed at the 6-year visit, of the 35 NHYPO subjects with follow-up data, none of them developed overt hypoparathyroidism and only 15 (0·6%) had persistent evidence of NHYPO. This finding is in keeping with that reported by others; Cusano et al. [4] identified 68 subjects with NHYPO; none of whom developed overt hypoparathyroidism on follow-up and persistent disease noted in only 2 of the 26 subjects with follow-up data.
A few studies have shown that bone turnover marker levels are frankly low or low-normal in patients with hypoparathyroidism compared to normal subjects, [17] [18] [19] [20] and these findings are consistent with histomorphometric analysis. In particular, double tetracycline labelling of bone biopsy specimens has demonstrated that dynamic skeletal indices are suppressed in hypoparathyroid patients. [21] According to these data, NHYPO seems to be characterized by a 'low bone turnover' without a significant BMD change over time compared to normal individuals. In agreement, we found a significant reduction in serum levels of CTX, BAP and osteocalcin compared to subjects with no impairment of calcium metabolism.
Once again these findings confirm the key role of PTH in bone metabolism: a few studies have demonstrated that daily subcutaneous injections of PTH (1-84) result in a significant increase of bone formation and resorption markers (that were suppressed at baseline) in patients affected by hypoparathyroidism. [22] Our data on NHYPO raise questions on the appropriate management of these patients. Based on our findings, a 'watch and wait' philosophy may be suitable, but further data are needed before firm recommendations can be made. If patients are taking a medication that might induce hypocalcaemia, such as an antiresorptive drug (e.g. bisphosphonate, denosumab) or a loop diuretic (e.g. furosemide) then monitoring of serum calcium is recommended. The potential choice of treatment for subjects with NHYPO affected by osteoporosis is critical. Indeed powerful antiresorptive drugs, such as bisphosphonates and denosumab, could exacerbate the risk of adynamic bone disease by suppressing bone turnover. [23] Conversely, anabolic therapy could restore physiological bone turnover, [24] but we are not yet able to predict whether patients with NHYPO will experience an improvement in BMD. Indeed, in contrast to the effect of PTH (1-84) treatment in patients with osteoporosis, PTH (1-84) replacement therapy causes a general decrease in BMD at the hip, lumbar spine and whole body (apart from the forearm) in subjects with hypoparathyroidism. [22] Furthermore, despite significant changes in bone turnover, teriparatide did not provide any significant BMD improvement in hypoparathyroidism. [20] In particular, after 3 years of twice daily PTH treatment, BMD and bone mineral content (BMC) at the lumbar spine, femoral neck and whole body remained stable although there was a nonsignificant downward trend in BMD at the distal radius.
It was noteworthy that the prevalence of PHPT was high in our study. The biochemical abnormality of high serum calcium and high or high-normal PTH is also found in familial hypocalciuric hypercalcaemia, but we did not conduct any calcium excretion studies or gene testing to rule this out. Most of our cases were mild and the mean PTH was only at the upper limit of the reference interval for PTH; this might explain why most bone turnover markers were normal. The diagnosis of hypercalcaemia was made on samples after the second visit so this did not influence clinical management during the follow-up period.
It was also surprising that our rate of NPHPT was lower than in the MrOS study as many epidemiological studies have confirmed that hyperparathyroidism is less frequent in men. [25, 26] Other large retrospective studies have attempted to evaluate the epidemiology of NPHPT, but most did not rule out the main causes of secondary hyperparathyroidism. [27] [28] [29] The low prevalence of NPHPT in our population is most likely due to the high rate of vitamin D insufficiency (52·3%, data not shown) and eGFR reduction (62·4%, data not shown); the former due to geographical differences and the latter due to the higher mean age in comparison with Cusano's populations. The current definition of NPHPT probably tends to underestimate the prevalence of this category. Indeed, in agreement with Shibli-Rahhal and Paturi, [30] in our population, only 10·7% (data not shown) of older women with 25OHD < 50 nmol/l had an elevated PTH.
Circulating PTH concentrations display a large interindividual variability due to factors such as calcium intake and drugs such as lithium, MgSO 4 and diuretics which affect PTH levels. Moreover, this variance has been shown to have a strong heritable component, [1] although the genetic factors governing serum PTH concentrations remain unknown. Indeed, although it is well documented that loss of function and gain of function mutations of the CaSR lead, respectively, to hypercalcaemic and hypocalcaemic disorders, [31] no studies have assessed the status of the CaSR in NPHPT and hypoparathyroidism subjects. Another interesting area of research could be the evaluation of autoantibodies directed against the extracellular domain of the CaSR and NALP5 in subjects with NHYPO. Previous studies have identified the CaSR and NALP5 as parathyroid autoantibody targets in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy [32] and autoimmune hypocalciuric hypercalcaemia. [33] [34] [35] However, it is unclear whether these antibodies also contribute to the variability in serum PTH concentrations observed in normocalcaemic individuals.
Our study has a few limitations. We did not measure ionized calcium and fasting phosphate, we did not collect any biochemical data between the baseline visit and the second visit at 6 years, we only had a single value for each laboratory analyte at each time point, we lost a significant number of subjects over the course of the study, and BMD analysis was performed by two different instruments. Moreover, the prevalence of the different diagnostic categories might have been affected by long-term PTH storage. However, we do not consider it likely that the relatively high prevalence of NHYPO could be attributable to degradation of PTH during storage. Indeed, it has been estimated by some authors that there is about a 1% increase in intact PTH every year in women, with a faster rise after the menopause; [36, 37] therefore, the 9% increase we observed is likely to be agerelated rather than resulting from minor degradation. Furthermore, if the low prevalence of SHPT and relatively high prevalence of NHYPO had been attributable to degradation of PTH during storage, we would have also expected a low prevalence of hyperparathyroid hypercalcaemia (PHPT and FHH). Instead, we noted a high prevalence of hyperparathyroid hypercalcaemia.
In comparison with Cusano's findings, the prevalence of SHPT was quite low. This could be explained by the higher dietary calcium intake found in European countries compared to the US population. In one review, the mean calcium intake in the NHANES III study in older women was 600 mg/day, considerably lower than the estimates for the UK (800 mg), France (850 mg) and Germany (970 mg). [38] This is the first large population-based study to investigate the prevalence and metabolic bone status of NHYPO in postmenopausal women. It is fairly common, not always persistent and is characterized by low bone turnover.
